Cargando…

Efficient Distribution of a Novel Zirconium-89 Labeled Anti-cd20 Antibody Following Subcutaneous and Intravenous Administration in Control and Experimental Autoimmune Encephalomyelitis-Variant Mice

Objective: To investigate the imaging and biodistribution of a novel zirconium-89 ((89)Zr)-labeled mouse anti-cd20 monoclonal antibody (mAb) in control and experimental autoimmune encephalomyelitis (EAE) mice following subcutaneous (s. c.) and intravenous (i.v.) administration. Background: Anti-cd20...

Descripción completa

Detalles Bibliográficos
Autores principales:	Migotto, Mary-Anne, Mardon, Karine, Orian, Jacqueline, Weckbecker, Gisbert, Kneuer, Rainer, Bhalla, Rajiv, Reutens, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813232/ https://www.ncbi.nlm.nih.gov/pubmed/31681317 http://dx.doi.org/10.3389/fimmu.2019.02437

Ejemplares similares

Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration
por: Torres, Julia Baguña, et al.
Publicado: (2022)

Recent Advances in Zirconium-89 Chelator Development
por: Bhatt, Nikunj B., et al.
Publicado: (2018)

The Race for Hydroxamate-Based Zirconium-89 Chelators
por: Feiner, Irene V. J., et al.
Publicado: (2021)

Cerebellar pathology in multiple sclerosis and experimental autoimmune encephalomyelitis: current status and future directions
por: Maxwell, Dain L., et al.
Publicado: (2023)

Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89
por: Bhatt, Nikunj B., et al.
Publicado: (2017)

Effect of Subcutaneous Anti-CD20 Antibody-Mediated B Cell Depletion on Susceptibility to Pneumocystis Infection in Mice
por: Dai, Guixiang, et al.
Publicado: (2021)

In Vitro and In Vivo Characterization of (89)Zirconium-Labeled Lintuzumab Molecule
por: Allen, Kevin J. H., et al.
Publicado: (2022)

Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model
por: Baker, David, et al.
Publicado: (2019)

Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease
por: Laban, Kamil G., et al.
Publicado: (2019)

Zirconium-89 labelled rituximab PET-CT imaging of Graves’ orbitopathy
por: de Keizer, Bart, et al.
Publicado: (2019)

Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation
por: Mostafa, Ahmed M. A., et al.
Publicado: (2023)

Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development
por: Pandya, Darpan N., et al.
Publicado: (2017)

Immunomodulation Eliminates Inflammation in the Hippocampus in Experimental Autoimmune Encephalomyelitis, but Does Not Ameliorate Anxiety-Like Behavior
por: Kocovski, Pece, et al.
Publicado: (2021)

Promising Performance of 4HMS, a New Zirconium-89 Octadendate Chelator
por: Alnahwi, Aiman H., et al.
Publicado: (2020)

Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients
por: van de Watering, Floor C. J., et al.
Publicado: (2014)

Development of Nanosome-Encapsulated Honokiol for Intravenous Therapy Against Experimental Autoimmune Encephalomyelitis
por: Hsiao, Yai-Ping, et al.
Publicado: (2020)

In Vivo Integrity and Biological Fate of Chelator-Free Zirconium-89-Labeled Mesoporous Silica Nanoparticles
por: Chen, Feng, et al.
Publicado: (2015)

A new technique for the radiolabelling of mixed leukocytes with zirconium‐89 for inflammation imaging with positron emission tomography
por: Fairclough, M., et al.
Publicado: (2016)

Preparation of Zirconium-89 Solutions for Radiopharmaceutical Purposes: Interrelation Between Formulation, Radiochemical Purity, Stability and Biodistribution
por: Larenkov, Anton, et al.
Publicado: (2019)

Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89
por: Zhai, Chuangyan, et al.
Publicado: (2019)

Molecular Imaging of Inflammation in a Mouse Model of Atherosclerosis Using a Zirconium-89-Labeled Probe
por: Ahmed, Mona, et al.
Publicado: (2020)

Optimal Attenuation of Experimental Autoimmune Encephalomyelitis by Intravenous Immunoglobulin Requires an Intact Interleukin-11 Receptor
por: Figueiredo, Carlyn A., et al.
Publicado: (2014)

Combined Treatment with Zinc Aspartate and Intravenous Immunoglobulins (IVIGs) Ameliorates Experimental Autoimmune Encephalomyelitis (EAE)
por: Straubel, Diana, et al.
Publicado: (2018)

Platelet Depletion is Effective in Ameliorating Anxiety-Like Behavior and Reducing the Pro-Inflammatory Environment in the Hippocampus in Murine Experimental Autoimmune Encephalomyelitis
por: Kocovski, Pece, et al.
Publicado: (2019)

Letter to the editor regarding ‘‘Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia’
por: Zarzuela, Donna, et al.
Publicado: (2021)

Correction: Optimal Attenuation of Experimental Autoimmune Encephalomyelitis by Intravenous Immunoglobulin Requires an Intact Interleukin-11 Receptor
Publicado: (2014)

Engineering Intrinsically Zirconium‐89 Radiolabeled Self‐Destructing Mesoporous Silica Nanostructures for In Vivo Biodistribution and Tumor Targeting Studies
por: Goel, Shreya, et al.
Publicado: (2016)

Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images
por: Jauw, Yvonne W. S., et al.
Publicado: (2018)

In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab
por: Roy, Jyoti, et al.
Publicado: (2021)

On the Versatility of Nanozeolite Linde Type L for Biomedical Applications: Zirconium-89 Radiolabeling and In Vivo Positron Emission Tomography Study
por: Lacerda, Sara, et al.
Publicado: (2022)

EXM 89-20
por: Daems, G
Publicado: (1989)

Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine
por: Paris, Daniel, et al.
Publicado: (2013)

Environmental Influences in Experimental Autoimmune Encephalomyelitis
por: Constantinescu, Cris S
Publicado: (2005)

p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging
por: Perk, Lars R., et al.
Publicado: (2009)

Subcutaneous Extravasation of Sr-89: Usefulness of Bremsstrahlung Imaging in Confirming Sr-89 Extravasation and in the Decision Making for the Choice of Treatment Strategies for Local Radiation Injuries Caused by Sr-89 Extravasation
por: Kawabe, Joji, et al.
Publicado: (2013)

On the Subcutaneous Injection of Blood, Infusion (Subcutaneous) and Intravenous Transfusion
por: Oehler,, et al.
Publicado: (1888)

(89)Zirconium-labelled girentuximab ((89)Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma
por: Al-Zubaidi, Mohammed, et al.
Publicado: (2022)

Zirconium
por: Miller, George L
Publicado: (1954)

Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®
por: Liapis, Vasilios, et al.
Publicado: (2020)

Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor
por: Rudd, Stacey E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j2hhjfiak787pi1i37d0aadlr8